These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25355696)

  • 21. Perspectives on anti-CD47 antibody treatment for experimental cancer.
    Unanue ER
    Proc Natl Acad Sci U S A; 2013 Jul; 110(27):10886-7. PubMed ID: 23784781
    [No Abstract]   [Full Text] [Related]  

  • 22. Inhibitory signaling through signal regulatory protein-α is not sufficient to explain the antitumor activities of CD47 antibodies.
    Soto-Pantoja DR; Miller TW; Frazier WA; Roberts DD
    Proc Natl Acad Sci U S A; 2012 Oct; 109(42):E2842; author reply E2844-5. PubMed ID: 22923696
    [No Abstract]   [Full Text] [Related]  

  • 23. A rare case of large cell neuroendocrine carcinoma of the urinary bladder evaluated by ¹⁸F-FDG-PET/CT.
    Treglia G; Paone G; Flores B; Venzi G; Ceriani L; Giovanella L
    Rev Esp Med Nucl Imagen Mol; 2014; 33(5):312-3. PubMed ID: 24440201
    [No Abstract]   [Full Text] [Related]  

  • 24. Lymphoma spread? Target CD47-SIRPα!
    Spaargaren M
    Blood; 2011 Nov; 118(18):4762-4. PubMed ID: 22053171
    [No Abstract]   [Full Text] [Related]  

  • 25. Is targeting of CD47-SIRPα enough for treating hematopoietic malignancy?
    Zhao XW; Kuijpers TW; van den Berg TK
    Blood; 2012 May; 119(18):4333-4; author reply 4334-5. PubMed ID: 22555661
    [No Abstract]   [Full Text] [Related]  

  • 26. Imaging in bladder cancer: present role and future perspectives.
    Totaro A; Pinto F; Brescia A; Racioppi M; Cappa E; D'Agostino D; Volpe A; Sacco E; Palermo G; Valentini A; Bassi P
    Urol Int; 2010; 85(4):373-80. PubMed ID: 20962513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diuretic ¹⁸F-FDG PET/CT for therapy monitoring in urothelial bladder cancer.
    Coquan E; Lasnon C; Joly F; Lefort JM; Aide N
    Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1818-9. PubMed ID: 24893789
    [No Abstract]   [Full Text] [Related]  

  • 29. Adenocarcinoma in an Indiana pouch on PET-CT.
    Ho L; Henderson R; Jadvar H
    Clin Nucl Med; 2007 Jan; 32(1):57-8. PubMed ID: 17179810
    [No Abstract]   [Full Text] [Related]  

  • 30. Current role of PET, CT, MR for invasive bladder cancer.
    Lawrentschuk N; Lee ST; Scott AM
    Curr Urol Rep; 2013 Apr; 14(2):84-9. PubMed ID: 23392958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 18 F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study.
    Hitier-Berthault M; Ansquer C; Branchereau J; Renaudin K; Bodere F; Bouchot O; Rigaud J
    Int J Urol; 2013 Aug; 20(8):788-96. PubMed ID: 23279605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [MODERN PRINCIPLES OF ENDOSCOPY. COMPARATIVE STUDY WITH CLASSICAL ENDOSCOPES, WITH QUARTZ CONDUCTORS AND FIBRILLAR OPTICS, USED IN GASTROENTEROLOGY. TRENDS IN DEVELOPMENT OF ENDOPHOTOCINEMATOGRAPHY AND ENDOTELEVISION].
    STECLACI A; STOICHITA S; KARI L
    Stud Cercet Med Interna; 1965; 40():205-16. PubMed ID: 14338266
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.
    Apolo AB; Riches J; Schöder H; Akin O; Trout A; Milowsky MI; Bajorin DF
    J Clin Oncol; 2010 Sep; 28(25):3973-8. PubMed ID: 20679618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blockade of CD47 or SIRPα: a new cancer immunotherapy.
    Murata Y; Saito Y; Kotani T; Matozaki T
    Expert Opin Ther Targets; 2020 Oct; 24(10):945-951. PubMed ID: 32799682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on use of enhanced imaging to optimize lymphadenectomy in patients undergoing minimally invasive surgery for urothelial cancer of the bladder.
    Lusuardi L; Janetschek G
    Curr Urol Rep; 2013 Apr; 14(2):124-9. PubMed ID: 23341374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell 'don't eat me' signals off and 'eat me' signals on.
    Mohanty S; Aghighi M; Yerneni K; Theruvath JL; Daldrup-Link HE
    Mol Oncol; 2019 Oct; 13(10):2049-2061. PubMed ID: 31376208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
    Willingham SB; Volkmer JP; Gentles AJ; Sahoo D; Dalerba P; Mitra SS; Wang J; Contreras-Trujillo H; Martin R; Cohen JD; Lovelace P; Scheeren FA; Chao MP; Weiskopf K; Tang C; Volkmer AK; Naik TJ; Storm TA; Mosley AR; Edris B; Schmid SM; Sun CK; Chua MS; Murillo O; Rajendran P; Cha AC; Chin RK; Kim D; Adorno M; Raveh T; Tseng D; Jaiswal S; Enger PØ; Steinberg GK; Li G; So SK; Majeti R; Harsh GR; van de Rijn M; Teng NN; Sunwoo JB; Alizadeh AA; Clarke MF; Weissman IL
    Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6662-7. PubMed ID: 22451913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety.
    Yu XY; Qiu WY; Long F; Yang XP; Zhang C; Xu L; Chang HY; Du P; Hou XJ; Yu YZ; Zeng DD; Wang S; Sun ZW
    Biochimie; 2018 Aug; 151():54-66. PubMed ID: 29864508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors.
    Liu X; Pu Y; Cron K; Deng L; Kline J; Frazier WA; Xu H; Peng H; Fu YX; Xu MM
    Nat Med; 2015 Oct; 21(10):1209-15. PubMed ID: 26322579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD47-targeted bismuth selenide nanoparticles actualize improved photothermal therapy by increasing macrophage phagocytosis of cancer cells.
    Guo Z; Liu Y; Zhou H; Zheng K; Wang D; Jia M; Xu P; Ma K; Cui C; Wang L
    Colloids Surf B Biointerfaces; 2019 Dec; 184():110546. PubMed ID: 31606701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.